[{"id":"e84b6fb9-58df-4ebb-b205-149e85c08e31","acronym":"","url":"https://clinicaltrials.gov/study/NCT04626739","created_at":"2021-01-19T20:35:41.203Z","updated_at":"2024-07-02T16:36:38.698Z","phase":"Phase 1","brief_title":"CAR-T Cells in Treating Patients With Relapsed or Refractory NHL","source_id_and_acronym":"NCT04626739","lead_sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive • CD19 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • CD19 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Senl_22 • Senl_H19x22P"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 04/01/2020","start_date":" 04/01/2020","primary_txt":" Primary completion: 03/30/2023","primary_completion_date":" 03/30/2023","study_txt":" Completion: 03/30/2023","study_completion_date":" 03/30/2023","last_update_posted":"2020-11-13"},{"id":"2a21b70e-502b-4d34-849c-e7ccf37ca4dd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04546906","created_at":"2021-01-18T21:45:01.405Z","updated_at":"2024-07-02T16:36:41.044Z","phase":"","brief_title":"Safety and Efficacy Study of CD22 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT04546906","lead_sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","biomarkers":" IFNG • IL6 • TNFA • CD22 • IL10","pipe":" | ","alterations":" CD22 positive","tags":["IFNG • IL6 • TNFA • CD22 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • S1904 • Senl_22"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/01/2020","start_date":" 09/01/2020","primary_txt":" Primary completion: 09/01/2022","primary_completion_date":" 09/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2020-09-14"}]